Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company

Sun Pharmaceutical Industries Limited clinical trials

The registry lists 327 studies whose lead sponsor is Sun Pharmaceutical Industries Limited or one of 9 companies grouped under it. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.

Keep track of what changes. Save the Sun Pharmaceutical Industries Limited studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

Status

Completed: 283
Terminated: 16
Recruiting: 10
Withdrawn: 10
Active, not recruiting: 7
Temporarily not available: 1

Phase

Phase 1: 102
Phase 2: 60
Phase 3: 57
Phase 4: 12
Early Phase 1: 7

Where

United States: 190
India: 48
Canada: 31
Poland: 15
Australia: 14
Spain: 14

Focus areas

Conditions Sun Pharmaceutical Industries Limited leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Acne Vulgaris30 Malnutrition23 Psoriasis22 Keratosis, Actinic16 Alopecia Areata10

Studies

Recruiting first, then most recently updated. Showing 50 of 327. Browse all 327 →

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia AreataRecruitingNCT07617597Phase 3
Sponsor listed in the registry: Sun Pharma Japan Limited
An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the FaceRecruitingNCT07729579Phase 1
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.RecruitingNCT07042100Phase 1
Sponsor listed in the registry: Sun Pharma Advanced Research Company Limited · Sun Pharma Advanced Research Company Limited — formerly part of Sun Pharmaceutical Industries Limited
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.RecruitingNCT05422911Phase 2
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and ScalpRecruitingNCT07144345Phase 3
Sponsor listed in the registry: Sun Pharmaceutical Industries, Inc.
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper ExtremitiesRecruitingNCT07144852Phase 3
Sponsor listed in the registry: Sun Pharmaceutical Industries, Inc.
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes MellitusRecruitingNCT07282743Phase 2
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal InsufficiencyRecruitingNCT07385547Phase 1
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia AreataRecruitingNCT07133308Phase 3
Sponsor listed in the registry: Sun Pharmaceutical Industries, Inc.
Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With TildrakizumabRecruitingNCT03992729
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.Active, not recruitingNCT06611163Phase 3
A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.CompletedNCT07795567Phase 1
Sponsor listed in the registry: Sun Pharmaceutical Industries, Inc.
A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne PatientsCompletedNCT06415279Phase 4
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML TherapiesTerminatedNCT02629692Phase 1/2
Sponsor listed in the registry: Sun Pharma Advanced Research Company Limited · Sun Pharma Advanced Research Company Limited — formerly part of Sun Pharmaceutical Industries Limited
A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.CompletedNCT07546214Phase 1
Sponsor listed in the registry: Sun Pharmaceutical Industries, Inc.
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque PsoriasisActive, not recruitingNCT03997786Phase 2/3
Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous TreatmentsTemporarily not availableNCT07517315
Sponsor listed in the registry: Sun Pharma Advanced Research Company Limited · Sun Pharma Advanced Research Company Limited — formerly part of Sun Pharmaceutical Industries Limited
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail PsoriasisCompletedNCT03897075Phase 3
Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell CarcinomaCompletedNCT04066504
A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne VulgarisCompletedNCT07469228Phase 1
Sponsor listed in the registry: Sun Pharmaceutical Industries, Inc.
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)Active, not recruitingNCT04314531Phase 3
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic ArthritisActive, not recruitingNCT04991116Phase 3
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne PatientsActive, not recruitingNCT06425900Phase 4
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque PsoriasisCompletedNCT04566666Phase 2
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)CompletedNCT04314544Phase 3
A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With AcneCompletedNCT06415305Phase 4
To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic DermatitisCompletedNCT04684485Phase 2
European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataCompletedNCT05041803Phase 3
Sponsor listed in the registry: Sun Pharmaceutical Industries, Inc.
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataActive, not recruitingNCT03898479Phase 2/3
Sponsor listed in the registry: Sun Pharmaceutical Industries, Inc.
A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of AcneCompletedNCT06336603Phase 4
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706TerminatedNCT03655236Phase 2
Sponsor listed in the registry: Sun Pharma Advanced Research Company Limited · Sun Pharma Advanced Research Company Limited — formerly part of Sun Pharmaceutical Industries Limited
A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of AcneCompletedNCT06336629Phase 4
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne VulgarisCompletedNCT04321070Phase 1
Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLCTerminatedNCT04786964Phase 3
Sponsor listed in the registry: Checkpoint Therapeutics, Inc. · First submitted before Checkpoint Therapeutics, Inc. became part of Sun Pharmaceutical Industries Limited
A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone PatientsCompletedNCT06415292Phase 4
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersActive, not recruitingNCT03212404Phase 1
Sponsor listed in the registry: Checkpoint Therapeutics, Inc. · First submitted before Checkpoint Therapeutics, Inc. became part of Sun Pharmaceutical Industries Limited
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne VulgarisCompletedNCT06733402Phase 1
Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.CompletedNCT03552276Phase 2/3
A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.CompletedNCT06673641Phase 1
Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited
A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.CompletedNCT06673654Phase 1
Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia AreataCompletedNCT04784533Phase 2
Sponsor listed in the registry: Concert Pharmaceuticals · First submitted before Concert Pharmaceuticals became part of Sun Pharmaceutical Industries Limited
Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee OsteoarthritisCompletedNCT04506463Phase 2
To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical GelCompletedNCT03094403Phase 1
Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited
A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.CompletedNCT06305637Phase 1
Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited
Effect of Cequa™ in Subjects With Dry Eye DiseaseCompletedNCT04357795Phase 4
A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT05022004Phase 3
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With SchizophreniaCompletedNCT04158687Phase 2
Sponsor listed in the registry: Concert Pharmaceuticals · First submitted before Concert Pharmaceuticals became part of Sun Pharmaceutical Industries Limited
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne VulgarisCompletedNCT06063473Phase 1
Sponsor listed in the registry: Taro Pharmaceuticals USA · First submitted after Taro Pharmaceuticals USA became part of Sun Pharmaceutical Industries Limited
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)CompletedNCT04797650Phase 3
Sponsor listed in the registry: Concert Pharmaceuticals · First submitted before Concert Pharmaceuticals became part of Sun Pharmaceutical Industries Limited
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp PsoriasisCompletedNCT03897088Phase 3